Earnings

Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Lowers FY2026 Sales Guidance from $600.000M-$610.000M to $590.000M-$595.000M vs $604.782M Est

Nov 2, 2026 · 04:19 PM ET· updated 1h ago

Bioventus (NASDAQ:BVS) affirms FY2026 Adj EPS guidance from $0.75-$0.79 to $0.75-$0.79 vs $0.78 analyst estimate. Lowers FY2026 sales outlook from $600.000 million-$610.000 million to $590.000 million-$595.000 million

Why It Matters

Bioventus kept its profit promise but expects less money from sales. Watch whether the company can still grow its business going forward.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BVS11.62

-1.71 (-12.80%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.